Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017 Dec;14(12):717-734.
doi: 10.1038/nrclinonc.2017.101. Epub 2017 Jul 25.

The Immune Contexture in Cancer Prognosis and Treatment

Affiliations
Review

The Immune Contexture in Cancer Prognosis and Treatment

Wolf H Fridman et al. Nat Rev Clin Oncol. .

Abstract

Immunotherapy is currently the most rapidly advancing area of clinical oncology, and provides the unprecedented opportunity to effectively treat, and even cure, several previously untreatable malignancies. A growing awareness exists of the fact that the success of chemotherapy and radiotherapy, in which the patient's disease can be stabilized well beyond discontinuation of treatment (and occasionally is cured), also relies on the induction of a durable anticancer immune response. Indeed, the local immune infiltrate undergoes dynamic changes that accompany a shift from a pre-existing immune response to a therapy-induced immune response. As a result, the immune contexture, which is determined by the density, composition, functional state and organization of the leukocyte infiltrate of the tumour, can yield information that is relevant to prognosis, prediction of a treatment response and various other pharmacodynamic parameters. Several complementary technologies can be used to explore the immune contexture of tumours, and to derive biomarkers that could enable the adaptation of individual treatment approaches for each patient, as well as monitoring a response to anticancer therapies.

Similar articles

See all similar articles

Cited by 185 articles

See all "Cited by" articles

References

    1. N Engl J Med. 2015 Oct 22;373(17):1627-39 - PubMed
    1. J Clin Oncol. 2008 Sep 20;26(27):4410-7 - PubMed
    1. Cancer Discov. 2014 Jun;4(6):674-87 - PubMed
    1. Cancer Immunol Res. 2016 Nov;4(11):936-947 - PubMed
    1. Cell. 2015 Apr 9;161(2):205-14 - PubMed

Substances

Feedback